Tag Archives: generic
Biosimilars: How the EMEA Got It Right (Part 1)
I don’t think anyone disagrees that: Access to life-saving medications for all patients must be granted through a patient-focused, science-based application of a logical, open, and rational process, and that For patients to gain the greatest possible benefits, biologics with … Continue reading
Filed under Biosimilars Legislation